Detalhe da pesquisa
1.
Plain language summary: Can declines in prostate-specific antigen level indicate how long patients with advanced prostate cancer will live when treated with enzalutamide?
Future Oncol
; 19(29): 1953-1960, 2023 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-37585665
2.
The role of mean corpuscular volume and red cell distribution width in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors: the MARECAP retrospective study.
Ther Adv Urol
; 15: 17562872231187216, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37492625
3.
Integrating Red Blood Cell Features and Hemoglobin Levels in Metastatic Renal Cell Carcinoma Patients Treated with Pazopanib or Cabozantinib: An Easily Exploitable Prognostic Score.
Front Biosci (Elite Ed)
; 15(3): 20, 2023 07 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-37743233
4.
Erratum to 'Clinical progression is associated with poor prognosis whatever the treatment line in metastatic castration-resistant prostate cancer: The CATS international database' [European Journal of Cancer, Volume 125 (January 2020) Pages 153-163].
Eur J Cancer
; 137: 290-291, 2020 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-32723589